nach oben

Medical Oncology

Erschienen in:

01.03.2015 | Short Communication

BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis

verfasst von: Ye Yang, Chunyan Gu, Chen Luo, Fei Li, Min Wang

Erschienen in: Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Multiple myeloma (MM) is the second most common hematopoietic malignancy characterized by plasma cell proliferative disorder. In this study, we disclosed that expression of BUB1B significantly increased in high-risk myeloma patients especially in the most aggressive myeloma genetic subgroups of proliferation. Increased BUB1B expression promotes MM cell proliferation. Mechanism study showed that BUB1B expression was highly correlated to CDC20 and CCNB1/2 expression in MM cells, leading to increased MM cell proliferation. Therefore, BUB1B may be a potential target for MM treatment especially for high-risk MM patients.

Richards T, Weber D. Advances in treatment for relapses and refractory multiple myeloma. Med Oncol (Northwood, London, England). 2010;27(Suppl 1):S25–42. doi:10.1007/s12032-009-9407-5.CrossRef

Laubach JP, Richardson PG, Anderson KC. The evolution and impact of therapy in multiple myeloma. Med Oncol (Northwood, London, England). 2010;27(Suppl 1):S1–6. doi:10.1007/s12032-010-9442-2.CrossRef

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020–8. doi:10.1182/blood-2005-11-013458.PubMedCentralCrossRefPubMed

Kumar S. Treatment of newly diagnosed multiple myeloma: advances in current therapy. Med Oncol (Northwood, London, England). 2010;27(Suppl 1):S14–24. doi:10.1007/s12032-009-9370-1.CrossRef

Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013;23(1):48–62. doi:10.1016/j.ccr.2012.12.001.PubMedCentralCrossRefPubMed

Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K, Hirata Y. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res. 2002;62(1):13–7.PubMed

Park HY, Jeon YK, Shin HJ, Kim IJ, Kang HC, Jeong SJ, et al. Differential promoter methylation may be a key molecular mechanism in regulating BubR1 expression in cancer cells. Exp Mol Med. 2007;39(2):195–204. doi:10.1038/emm.2007.22.CrossRefPubMed

Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, Gabbert HE, et al. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer—association with tumour cell proliferation. J Pathol. 2003;200(1):16–22. doi:10.1002/path.1324.CrossRefPubMed

Burum-Auensen E, Deangelis PM, Schjolberg AR, Roislien J, Andersen SN, Clausen OP. Spindle proteins Aurora A and BUB1B, but not Mad2, are aberrantly expressed in dysplastic mucosa of patients with longstanding ulcerative colitis. J Clin Pathol. 2007;60(12):1403–8. doi:10.1136/jcp.2006.044305.PubMedCentralCrossRefPubMed

10.

Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, et al. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015. doi:10.1158/0008-5472.can-14-2362.

11.

Li Y, He N, Zhai C. Peperotetraphin inhibits the proliferation of human prostate cancer cells via induction of cell cycle arrest and apoptosis. Med Oncol (Northwood, London, England). 2015;32(2):468. doi:10.1007/s12032-014-0468-8.

12.

Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109(11):4995–5001. doi:10.1182/blood-2006-07-038703.PubMedCentralCrossRefPubMed

13.

Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010;1(1):22–33.PubMedCentralPubMed

14.

Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, et al. RARalpha2 expression confers myeloma stem cell features. Blood. 2013;122(8):1437–47. doi:10.1182/blood-2013-02-482919.PubMedCentralCrossRefPubMed

15.

Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X, et al. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia. 2014;28(5):1155–8. doi:10.1038/leu.2013.383.PubMedCentralCrossRefPubMed

16.

Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, et al. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget. 2014;5(23):11986–97.PubMedCentralPubMed

17.

Malureanu LA, Jeganathan KB, Hamada M, Wasilewski L, Davenport J, van Deursen JM. BubR1 N terminus acts as a soluble inhibitor of cyclin B degradation by APC/C(Cdc20) in interphase. Dev Cell. 2009;16(1):118–31. doi:10.1016/j.devcel.2008.11.004.PubMedCentralCrossRefPubMed

18.

Suijkerbuijk SJ, van Osch MH, Bos FL, Hanks S, Rahman N, Kops GJ. Molecular causes for BUBR1 dysfunction in the human cancer predisposition syndrome mosaic variegated aneuploidy. Cancer Res. 2010;70(12):4891–900. doi:10.1158/0008-5472.can-09-4319.PubMedCentralCrossRefPubMed

19.

Schliekelman M, Cowley DO, O’Quinn R, Oliver TG, Lu L, Salmon ED, et al. Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis. Cancer Res. 2009;69(1):45–54. doi:10.1158/0008-5472.can-07-6330.CrossRefPubMed

Titel: BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis
verfasst von: Ye Yang
Chunyan Gu
Chen Luo
Fei Li
Min Wang
Publikationsdatum: 01.03.2015
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 3/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-015-0542-x

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

CD40 expression and its prognostic significance in human gastric carcinoma

Mechanical characterization of cervical squamous carcinoma cells by atomic force microscopy at nanoscale

Clinical outcomes of CyberKnife stereotactic body radiotherapy for peripheral stage I non-small cell lung cancer

Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas

ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins

Capn4 promotes non-small cell lung cancer progression via upregulation of matrix metalloproteinase 2

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie